Morgan Stanley analyst Connor Lynagh maintains HF Sinclair (NYSE:DINO) with a Overweight and raises the price target from $65 to $70.
Nurix Therapeutics Q4 EPS $(0.87) Misses $(0.79) Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.79) by 10.13 percent. This is a 2.35 percent decrease over losses of $(0.85) per share
